Table 9 The first 10 enriched pathways using the whole list of relevant DEGs obtained from the Alzheimer GSE16759 data set without using genes’ group classification
PathwayName | Pvalue | FDRC | BonfC | \(|lg_{2}(P_{value})|\) | \(|lg_{2}(FDR(P_{value})|\) | \(|lg_{2}Bonf(P_{value})|\) |
|---|---|---|---|---|---|---|
(1) Post-translational protein modification | 8.20E-05 | 0.0390 | 0.0390 | 4.68 | 4.68 | 4.68 |
(2) Metabolism of proteins | 1.67E−04 | 0.0396 | 0.0793 | 4.66 | 3.66 | 3.66 |
(3) Neurophilin interactions with VEGF and VEGFR | 7.62E−04 | 0.1208 | 0.3625 | 3.05 | 1.46 | 1.46 |
(4) Disease | 0.0013 | 0.1574 | 0.6299 | 2.67 | 0.67 | 0.67 |
(5) VEGF binds to VEGFR leading to receptor dimerization | 0.0028 | 0.2679 | 1 | 1.90 | 0.00 | 0.00 |
(6) VEGF ligand–receptor interactions | 0.0028 | 0.2233 | 1 | 2.16 | 0.00 | 0.00 |
(7) Signaling by VEGF | 0.0029 | 0.1976 | 1 | 2.34 | 0.00 | 0.00 |
(8) Synthesis of 5-eicosatetraenoic acids | 0.0047 | 0.2827 | 1 | 1.82 | 0.00 | 0.00 |
(9) Signaling by receptor tyrosine Kinases | 0.0047 | 0.2534 | 1 | 1.98 | 0.00 | 0.00 |
(10) Synthesis of leukotrienes (LT) and Eoxins (EX) | 0.0049 | 0.2352 | 1 | 2.09 | 0.00 | 0.00 |